Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AstraZeneca PLC stock logo
AZN
AstraZeneca
$84.53
-0.6%
$78.97
$61.24
$86.57
$262.16B0.365.22 million shs14.25 million shs
GSK PLC Sponsored ADR stock logo
GSK
GSK
$43.53
+0.2%
$40.21
$31.72
$45.59
$88.55B0.535.15 million shs5.32 million shs
Haleon PLC Sponsored ADR stock logo
HLN
Haleon
$8.99
-0.4%
$9.44
$8.71
$11.42
$40.03B0.212.22 million shs7.28 million shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AstraZeneca PLC stock logo
AZN
AstraZeneca
-0.40%+1.66%+4.70%+19.56%+9.72%
GSK PLC Sponsored ADR stock logo
GSK
GSK
+0.14%-0.55%+6.21%+13.40%+7.90%
Haleon PLC Sponsored ADR stock logo
HLN
Haleon
-0.33%+1.52%-7.68%-9.44%-10.43%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AstraZeneca PLC stock logo
AZN
AstraZeneca
$84.53
-0.6%
$78.97
$61.24
$86.57
$262.16B0.365.22 million shs14.25 million shs
GSK PLC Sponsored ADR stock logo
GSK
GSK
$43.53
+0.2%
$40.21
$31.72
$45.59
$88.55B0.535.15 million shs5.32 million shs
Haleon PLC Sponsored ADR stock logo
HLN
Haleon
$8.99
-0.4%
$9.44
$8.71
$11.42
$40.03B0.212.22 million shs7.28 million shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AstraZeneca PLC stock logo
AZN
AstraZeneca
-0.40%+1.66%+4.70%+19.56%+9.72%
GSK PLC Sponsored ADR stock logo
GSK
GSK
+0.14%-0.55%+6.21%+13.40%+7.90%
Haleon PLC Sponsored ADR stock logo
HLN
Haleon
-0.33%+1.52%-7.68%-9.44%-10.43%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AstraZeneca PLC stock logo
AZN
AstraZeneca
2.80
Moderate Buy$86.001.74% Upside
GSK PLC Sponsored ADR stock logo
GSK
GSK
1.88
Reduce$37.38-14.13% Downside
Haleon PLC Sponsored ADR stock logo
HLN
Haleon
2.50
Moderate Buy$12.3337.17% Upside

Current Analyst Ratings Breakdown

Latest GSK, AZN, HLN, and DPH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/8/2025
AstraZeneca PLC stock logo
AZN
AstraZeneca
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy (B)
10/8/2025
GSK PLC Sponsored ADR stock logo
GSK
GSK
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C)
10/8/2025
Haleon PLC Sponsored ADR stock logo
HLN
Haleon
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C)
9/27/2025
AstraZeneca PLC stock logo
AZN
AstraZeneca
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy (B)
9/27/2025
GSK PLC Sponsored ADR stock logo
GSK
GSK
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C)
9/27/2025
Haleon PLC Sponsored ADR stock logo
HLN
Haleon
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C)
9/16/2025
Haleon PLC Sponsored ADR stock logo
HLN
Haleon
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOverweightEqual Weight
9/10/2025
Haleon PLC Sponsored ADR stock logo
HLN
Haleon
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeNeutralBuy
(Data available from 10/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AstraZeneca PLC stock logo
AZN
AstraZeneca
$56.50B4.64$6.23 per share13.56$13.18 per share6.41
GSK PLC Sponsored ADR stock logo
GSK
GSK
$31.63B2.80$5.60 per share7.77$8.07 per share5.39
Haleon PLC Sponsored ADR stock logo
HLN
Haleon
$14.35B2.79$0.50 per share18.13$4.58 per share1.96
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AstraZeneca PLC stock logo
AZN
AstraZeneca
$7.04B$2.6631.7816.911.5714.68%32.84%12.87%11/6/2025 (Estimated)
GSK PLC Sponsored ADR stock logo
GSK
GSK
$3.29B$2.1620.159.361.9510.81%49.22%11.31%10/29/2025 (Estimated)
Haleon PLC Sponsored ADR stock logo
HLN
Haleon
$1.84B$0.3923.0418.342.67N/AN/AN/A10/30/2025 (Estimated)

Latest GSK, AZN, HLN, and DPH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/6/2025Q3 2025
AstraZeneca PLC stock logo
AZN
AstraZeneca
$1.14N/AN/AN/A$14.75 billionN/A
10/29/2025Q3 2025
GSK PLC Sponsored ADR stock logo
GSK
GSK
$1.22N/AN/AN/A$8.21 billionN/A
7/30/2025Q2 2025
GSK PLC Sponsored ADR stock logo
GSK
GSK
$1.12$1.23+$0.11$0.94$7.92 billion$10.64 billion
7/29/2025Q2 2025
AstraZeneca PLC stock logo
AZN
AstraZeneca
$1.09$1.09N/A$0.79$14.08 billion$14.46 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AstraZeneca PLC stock logo
AZN
AstraZeneca
$1.011.19%N/A37.97%N/A
GSK PLC Sponsored ADR stock logo
GSK
GSK
$1.683.86%N/A77.78%N/A
Haleon PLC Sponsored ADR stock logo
HLN
Haleon
$0.111.22%N/A28.21%N/A

Latest GSK, AZN, HLN, and DPH Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/1/2100
GSK PLC Sponsored ADR stock logo
GSK
GSK
quarterly$0.42064.3%8/15/20258/15/202510/9/2025
8/4/2025
Haleon PLC Sponsored ADR stock logo
HLN
Haleon
semi-annual$0.05551.9%8/15/20258/15/20259/18/2025
7/29/2025
AstraZeneca PLC stock logo
AZN
AstraZeneca
semi-annual$0.50502%8/8/20258/8/20259/8/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AstraZeneca PLC stock logo
AZN
AstraZeneca
0.55
0.86
0.67
GSK PLC Sponsored ADR stock logo
GSK
GSK
1.07
0.87
0.57
Haleon PLC Sponsored ADR stock logo
HLN
Haleon
0.48
0.87
0.63

Institutional Ownership

CompanyInstitutional Ownership
AstraZeneca PLC stock logo
AZN
AstraZeneca
20.35%
GSK PLC Sponsored ADR stock logo
GSK
GSK
15.74%
Haleon PLC Sponsored ADR stock logo
HLN
Haleon
6.67%

Insider Ownership

CompanyInsider Ownership
AstraZeneca PLC stock logo
AZN
AstraZeneca
N/A
GSK PLC Sponsored ADR stock logo
GSK
GSK
10.00%
Haleon PLC Sponsored ADR stock logo
HLN
Haleon
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
AstraZeneca PLC stock logo
AZN
AstraZeneca
94,3003.10 billionN/AOptionable
GSK PLC Sponsored ADR stock logo
GSK
GSK
68,6292.03 billion1.83 billionOptionable
Haleon PLC Sponsored ADR stock logo
HLN
Haleon
24,5614.46 billionN/ANot Optionable

Recent News About These Companies

Are Haleon's headaches set to ease? Here's one leading bank's take
Haleon's (HLN) "Hold (C)" Rating Reiterated at Weiss Ratings
Haleon (NYSE:HLN) Shares Gap Down on Analyst Downgrade

New MarketBeat Followers Over Time

Media Sentiment Over Time

AstraZeneca stock logo

AstraZeneca NASDAQ:AZN

$84.53 -0.51 (-0.60%)
Closing price 04:00 PM Eastern
Extended Trading
$85.91 +1.38 (+1.63%)
As of 06:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

GSK stock logo

GSK NYSE:GSK

$43.52 +0.09 (+0.20%)
Closing price 03:59 PM Eastern
Extended Trading
$43.54 +0.02 (+0.03%)
As of 06:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Haleon stock logo

Haleon NYSE:HLN

$8.98 -0.04 (-0.39%)
Closing price 03:59 PM Eastern
Extended Trading
$8.98 -0.01 (-0.10%)
As of 05:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.